IM Cannabis Corp. (NASDAQ:IMCC – Free Report) – Analysts at Roth Capital lowered their Q3 2024 earnings per share estimates for IM Cannabis in a note issued to investors on Thursday, August 15th. Roth Capital analyst S. Fortune now forecasts that the company will post earnings per share of ($1.36) for the quarter, down from their previous forecast of ($0.90). The consensus estimate for IM Cannabis’ current full-year earnings is ($4.32) per share. Roth Capital also issued estimates for IM Cannabis’ Q4 2024 earnings at ($1.15) EPS, FY2024 earnings at ($5.61) EPS, Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($2.33) EPS.
IM Cannabis Price Performance
Shares of NASDAQ IMCC opened at $3.02 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.65 and a quick ratio of 0.40. The stock has a fifty day moving average price of $2.71 and a 200 day moving average price of $2.99. IM Cannabis has a 1-year low of $1.13 and a 1-year high of $8.10. The company has a market cap of $6.74 million, a PE ratio of -0.63 and a beta of 0.47.
Institutional Trading of IM Cannabis
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands.
See Also
- Five stocks we like better than IM Cannabis
- Election Stocks: How Elections Affect the Stock Market
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What Are Dividend Achievers? An Introduction
- 2 Option Strategies to Maximize Profits in a Bear Market
- What to Know About Investing in Penny Stocks
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.